A Retrospective Review of the Diagnostic Rate of Liver Biopsy in Abnormal Liver Tests with Non-Diagnostic Serology and Biochemistry

Chun Kit Hung, Monica Passi, M. Ullah, M. Ashamalla, Tai-ping Lee
{"title":"A Retrospective Review of the Diagnostic Rate of Liver Biopsy in Abnormal Liver Tests with Non-Diagnostic Serology and Biochemistry","authors":"Chun Kit Hung, Monica Passi, M. Ullah, M. Ashamalla, Tai-ping Lee","doi":"10.15226/2689-4432/2/1/00111","DOIUrl":null,"url":null,"abstract":"Abnormal liver function tests, defined as values greater than 2 standard deviations above the upper limits of normal, are noted to be present in up to 7.9% of the population in the United States. In about 69% of patients, they are unexplained by current standard serology or biochemistry markers investigating common viral, autoimmune, hereditary etiologies or inborn errors of metabolism [1, 2].Liver biopsy is considered the most accurate means of grading and staging of liver disease. However, there remains some controversy over whether or not it provides overall significant information in terms of establishing an etiology which would then be used to tailor patient management. [3] Moreover, there is the established possibility of sampling error and accompanying procedure complications during liver biopsy, albeit small [3, 4]. A number of studies have suggested that a high percentage of marker negative liver biopsies had fatty infiltration of the liver with varying degrees of inflammation, with mixed reports on whether there is an association with elements of the metabolic syndrome (obesity, diabetes, dyslipidemia) and improvement with reversal of this syndrome [5, 6, 7, 8]. Several other studies have also reported significant progressive liver disease and even cirrhosis in otherwise asymptomatic patients, who were biopsied with seemingly minor chronic elevations of liver enzymes. These findings subsequently significantly impacted the patient’s care [6, 9,10]. However, these were older studies where some biochemical markers were not excluded, and had conflicting conclusions with regards to the diagnostic rate of liver biopsies. [6, 8]. With rapidly advancing imaging technology and biochemical laboratory techniques, the current study seeks to re-evaluate the utility of liver biopsy. Specifically in patients with abnormal liver tests who have had non-diagnostic biochemical or radiographic workup, the rate at which liver biopsy provides a specific diagnosis that can lead to a change to management will be studied. Keywords: Liver biopsy; Metabolic syndrome; Fatty liver disease;","PeriodicalId":283817,"journal":{"name":"Journal of Hepatology, Gallbladder and Biliary Disease Research","volume":"67 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology, Gallbladder and Biliary Disease Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15226/2689-4432/2/1/00111","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abnormal liver function tests, defined as values greater than 2 standard deviations above the upper limits of normal, are noted to be present in up to 7.9% of the population in the United States. In about 69% of patients, they are unexplained by current standard serology or biochemistry markers investigating common viral, autoimmune, hereditary etiologies or inborn errors of metabolism [1, 2].Liver biopsy is considered the most accurate means of grading and staging of liver disease. However, there remains some controversy over whether or not it provides overall significant information in terms of establishing an etiology which would then be used to tailor patient management. [3] Moreover, there is the established possibility of sampling error and accompanying procedure complications during liver biopsy, albeit small [3, 4]. A number of studies have suggested that a high percentage of marker negative liver biopsies had fatty infiltration of the liver with varying degrees of inflammation, with mixed reports on whether there is an association with elements of the metabolic syndrome (obesity, diabetes, dyslipidemia) and improvement with reversal of this syndrome [5, 6, 7, 8]. Several other studies have also reported significant progressive liver disease and even cirrhosis in otherwise asymptomatic patients, who were biopsied with seemingly minor chronic elevations of liver enzymes. These findings subsequently significantly impacted the patient’s care [6, 9,10]. However, these were older studies where some biochemical markers were not excluded, and had conflicting conclusions with regards to the diagnostic rate of liver biopsies. [6, 8]. With rapidly advancing imaging technology and biochemical laboratory techniques, the current study seeks to re-evaluate the utility of liver biopsy. Specifically in patients with abnormal liver tests who have had non-diagnostic biochemical or radiographic workup, the rate at which liver biopsy provides a specific diagnosis that can lead to a change to management will be studied. Keywords: Liver biopsy; Metabolic syndrome; Fatty liver disease;
非诊断性血清学和生物化学异常肝检查中肝活检诊断率的回顾性分析
在美国,高达7.9%的人口中存在肝功能异常,定义为高于正常上限2个标准差。在大约69%的患者中,目前的标准血清学或生物化学标志物无法解释常见的病毒、自身免疫、遗传病因或先天性代谢错误[1,2]。肝活检被认为是肝脏疾病分级和分期最准确的方法。然而,它是否提供了建立病因学方面的全面重要信息,然后用于定制患者管理,仍然存在一些争议。[3]此外,在肝活检过程中存在采样误差和伴随的手术并发症的可能性,尽管很小[3,4]。许多研究表明,在标志物阴性的肝活检中,有高比例的肝脏存在脂肪浸润,并伴有不同程度的炎症,但关于其是否与代谢综合征(肥胖、糖尿病、血脂异常)相关以及该综合征逆转后的改善的报道不一[5,6,7,8]。其他几项研究也报道了在其他无症状的患者中出现明显的进行性肝病甚至肝硬化,这些患者在活检时发现肝酶似乎轻微的慢性升高。这些发现随后显著影响了患者的护理[6,9,10]。然而,这些是较早的研究,其中没有排除一些生化标志物,并且在肝活检的诊断率方面得出了相互矛盾的结论。(6、8)。随着影像技术和生化实验室技术的快速发展,当前的研究试图重新评估肝活检的效用。具体来说,对于肝脏检查异常且进行了非诊断性生化检查或放射检查的患者,将研究肝活检提供特定诊断并导致治疗改变的比率。关键词:肝活检;代谢综合征;脂肪肝;
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信